Categories Health Care
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene’s (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. During the pre-market trading session, both BMY and CELG increased about 4% and AMGN stock dropped about 1%.
Under the terms of the agreement and subject to the closing conditions, Amgen will acquire OTEZLA and related intellectual property, including any patents that primarily cover apremilast, as well as other assets and liabilities related to OTEZLA. The agreement includes the transfer of Celgene employees primarily dedicated to OTEZLA.
“This agreement represents an important step toward completing our pending merger with Celgene. It also demonstrates the tremendous achievement of the Celgene team in establishing OTEZLA as an important medicine for patients with psoriasis, psoriatic arthritis and Behçet’s Disease,” said Bristol-Myers CEO Giovanni Caforio.
Also read: Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Shareholders of Celgene and Bristol-Myers approved the merger in April. In light of the concerns expressed by the U.S. Federal Trade Commission (FTC), Bristol-Myers announced its plan to divest OTEZLA business in June. The next month, European Commission approved the merger.
When Celgene reported its Q2 results, the company projected OTEZLA sales to be about $1.9 billion in 2019. Sales of OTEZLA surged 31% to $493 million in the second quarter ended June 30, 2019.
Amgen expects the addition of OTEZLA to positively impact its financial results, including an immediate accretion to its non-GAAP EPS. Bristol-Myers plans to prioritize the use of proceeds from the OTEZLA divestiture for its debt reduction.
Bristol-Myers Squibb also announced that it is increasing its previously planned $5 billion accelerated share repurchase to $7 billion. The share repurchase will be executed following closing of the pending Bristol-Myers Squibb merger with Celgene, subject to Board approval.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to
Key highlights from Exxon Mobil Corporation’s (XOM) Q3 2024 earnings results
Exxon Mobil Corporation (NYSE: XOM) reported its third quarter 2024 earnings results today. Total revenues and other income remained relatively flat at $90 billion compared to the same period a
AAPL Earnings: Apple Q4 2024 sales rise 6% YoY, beat estimates
Apple Inc. (NASDAQ: AAPL) reported an increase in revenues for the fourth quarter of 2024. The top line came in above estimates. The gadget giant generated revenues of $94.9 billion
Comments
Comments are closed.